# Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke

> **NCT06648304** · PHASE3 · COMPLETED · sponsor: **Shanghai Auzone Biological Technology Co., Ltd.** · enrollment: 614 (actual)

## Conditions studied

- Acute Ischemic Stroke

## Interventions

- **DRUG:** TTYP01 tablets
- **DRUG:** Placebo (Simulant TTYP01 Tablets)

## Key facts

- **NCT ID:** NCT06648304
- **Lead sponsor:** Shanghai Auzone Biological Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-04-25
- **Primary completion:** 2024-06-17
- **Final completion:** 2024-06-17
- **Target enrollment:** 614 (ACTUAL)
- **Last updated:** 2025-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06648304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06648304, "Evaluate the Efficacy and Safety of TTYP01 Tablets in the Treatment of Acute Ischemic Stroke". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06648304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*